Clinical trials
Placebo - Control clinical trials
Below are recruiting placebo - control clinical trials, each written for real people, not researchers. We’re tracking 3,955 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07409922RecruitingPhase 1
Testing KR23343 in healthy volunteers
This study tests a new medicine, KR23343, in healthy adults to see how the body handles it at different doses. It helps find the right dose and check for any early side effects.
ShanghaiAges 18–45 - NCT07341386RecruitingPhase 4
Preventing herpes outbreaks in autoimmune rheumatic diseases
This trial tests whether a medicine called acyclovir can prevent herpes simplex outbreaks in people who also have an autoimmune rheumatic disease. It may help reduce the number of painful cold sores or genital herpes episodes you experience.
São Paulo, São PauloAges 12 years+ - NCT06674109RecruitingPhase 4
Testing a diabetes drug for gout prevention
This study tests if a type 2 diabetes medication (SGLT2 inhibitor) can help people with frequent gout flares. It aims to lower uric acid levels and reduce flare-ups.
Boston, MassachusettsAges 18–80 - NCT07674667RecruitingPhase 1/Phase 2
Testing a treatment to restore UNC13A function in ALS
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
MunichAges 18–75 - NCT07729839RecruitingPhase 1
Study of ADB116 injection for healthy volunteers
This trial tests a new medicine called ADB116 in healthy people to see how safe it is and how the body processes it. The results will help decide the right dose for future studies.
Guangzhou, GuangdongAges 18–45 - NCT05435547RecruitingPhase 4
Pre-surgery steroid medicine for autoimmune thyroid disease
This trial tests whether taking corticosteroids (anti-inflammatory medicines) before thyroid surgery is safe and helpful for people with autoimmune thyroid disease. It focuses on Graves’ or Hashimoto’s disease patients who are planning total thyroid removal.
Indianapolis, IndianaAges 18 years+ - NCT06224530Recruiting
Testing levetiracetam's effect on brain function in psychosis risk
This trial tests whether a single dose of levetiracetam, a medication that affects brain chemistry, can change brain function and thinking in people at risk for psychosis. The goal is to see if it might help prevent symptoms from worsening.
London, LondonAges 18–40 - NCT07287670RecruitingPhase 2
Testing MTX-474 for diffuse scleroderma
This trial tests an investigational drug called MTX-474 for people with diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The study aims to see if it can help slow or improve skin thickening and other symptoms.
Phoenix, ArizonaAges 18 years+ - NCT07704892RecruitingPhase 3
Study of efimosfermin for adults with cirrhosis from MASH
This trial tests a new drug, efimosfermin, to see if it is safe and effective for people with cirrhosis caused by MASH (a type of fatty liver disease). It may help improve liver health compared to a placebo.
Miami, FloridaAges 18–75 - NCT07594119RecruitingPhase 3
Testing RAP-219 to reduce seizures in focal epilepsy
This study tests a new medication called RAP-219 to see if it can reduce seizure frequency in adults with focal epilepsy (seizures starting in one area of the brain). You'll take the medication alongside your current seizure drugs and track your seizures daily using an app.
Bentonville, ArkansasAges 18–75 - NCT06979362RecruitingPhase 2
Study of CDR132L for heart failure with preserved pumping function
This trial tests if CDR132L can improve heart structure and function in people with a type of heart failure where the heart pumps normally but is stiff and thickened. It may help if you have heart failure with preserved ejection fraction and a thickened heart muscle.
Birmingham, AlabamaAges 40–84 - NCT05771675RecruitingEarly Phase 1
Simvastatin trial for symptom relief in pancreatitis
This early-phase study tests whether simvastatin can improve patient-reported symptoms in people with recurrent acute or chronic pancreatitis. It’s meant to see if the medicine is tolerable and helps with how you feel day to day.
Los Angeles, CaliforniaAges 18–75 - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT07225686RecruitingPhase 3
Maridebart Cafraglutide for sleep apnea in adults on CPAP
This study is testing whether a new medicine, called Maridebart Cafraglutide, can help people with obstructive sleep apnea who are already using a CPAP machine. The medicine may help with weight loss and potentially improve sleep apnea. Participants will either receive the medicine or a placebo (an inactive substance), and the study lasts for several months.
Northridge, CaliforniaAges 18–99 - NCT07566390RecruitingPhase 1
Testing a new weight-loss medicine in healthy adults
This early-stage study tests a new experimental medicine (NNC0113-5840) to see how it works in people who are overweight or have obesity. Researchers want to understand how the body processes this medicine and whether it's safe before testing it more widely.
Glendale, CaliforniaAges 18–55 - NCT07656415RecruitingPhase 3
Study of mitapivat for sickle cell disease patients who need blood transfusions
This study tests whether a daily pill called mitapivat can reduce the number of blood transfusions you need. It is for people with sickle cell disease who have had at least one transfusion in the past year and are not on regular transfusion therapy.
Indianapolis, IndianaAges 12 years+ - NCT07737665RecruitingPhase 4
Melatonin for better sleep in IBD patients in remission
This study tests whether melatonin (a natural sleep hormone) can improve sleep quality in people with inflammatory bowel disease (IBD) whose disease is quiet (in remission). If you have IBD and trouble sleeping, you may be able to join.
Bangkok Noi, BangkokAges 18 years+ - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
La Jolla, CaliforniaAges 18–75 - NCT07742735RecruitingPhase 3
Study of apraglutide for short bowel syndrome with intestinal failure
This study tests a new medicine called apraglutide, given as a shot, to see if it can help adults with short bowel syndrome and intestinal failure reduce their need for intravenous nutrition (parenteral support). The study compares apraglutide to a placebo (a shot with no medicine) to check if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07734493RecruitingPhase 1
Study of a new drug for acute schizophrenia symptoms
This trial tests an experimental medicine, LTX-001, for people with schizophrenia who are currently having a sudden worsening of symptoms. It aims to see if the drug can help reduce these acute symptoms.
Little Rock, ArkansasAges 18–55 - NCT07662135RecruitingPhase 3
A study of elecoglipron for type 2 diabetes with kidney problems
This trial tests a new medicine called elecoglipron to see if it helps control blood sugar in people with type 2 diabetes who also have reduced kidney function. You would continue taking your current SGLT2i medication (like dapagliflozin).
Peoria, ArizonaAges 18 years+ - NCT07664553RecruitingPhase 3
Testing a new diabetes tablet for people on insulin
This trial tests a new once-daily tablet (elecoglipron) against a placebo to see if it can help improve blood sugar control in adults with type 2 diabetes who are already on insulin. It may offer an additional treatment option to help manage your diabetes.
Little Rock, ArkansasAges 18 years+ - NCT07668999RecruitingPhase 1
Study of ZYG24004 for athlete's foot caused by fungus
This trial tests a new medication called ZYG24004 for athlete's foot (tinea pedis) caused by specific fungi. It may be a treatment option for people who have not had success with other antifungal treatments.
Beijing, Beijing MunicipalityAges 18–65 - NCT06775379RecruitingPhase 3
Azetukalner vs. placebo for major depression
This trial tests an investigational medication called Azetukalner against a placebo to see if it helps reduce symptoms of major depressive disorder. You may qualify if you are currently in a depressive episode that started in adulthood and have not tried or failed only a few antidepressants.
Phoenix, ArizonaAges 18–74
Hear when a new Placebo - Control trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for placebo - control?
- Yes. Clin2 currently lists 3,955 recruiting placebo - control studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a placebo - control trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a placebo - control trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.